These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 8192456)
1. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Brajtburg J; Elberg S; Kobayashi GS; Bolard J Antimicrob Agents Chemother; 1994 Feb; 38(2):300-6. PubMed ID: 8192456 [TBL] [Abstract][Full Text] [Related]
2. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Brajtburg J; Elberg S; Travis SJ; Kobayashi GS Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Ramos H; Brajtburg J; Marquez V; Cohen BE Drugs Exp Clin Res; 1995; 21(6):211-6. PubMed ID: 8907695 [TBL] [Abstract][Full Text] [Related]
4. Decrease in Fungizone toxicity induced by the use of Lipofundin as a dilutent: an in vitro study. de Araújo IB; Damasceno BP; de Medeiros TM; Soares LA; do Egito ES Curr Drug Deliv; 2005 Apr; 2(2):199-205. PubMed ID: 16305421 [TBL] [Abstract][Full Text] [Related]
5. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723 [TBL] [Abstract][Full Text] [Related]
6. Carrier effects on biological activity of amphotericin B. Brajtburg J; Bolard J Clin Microbiol Rev; 1996 Oct; 9(4):512-31. PubMed ID: 8894350 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Barwicz J; Gareau R; Audet A; Morisset A; Villiard J; Gruda I Biochem Biophys Res Commun; 1991 Dec; 181(2):722-8. PubMed ID: 1755853 [TBL] [Abstract][Full Text] [Related]
8. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. Shao K; Huang R; Li J; Han L; Ye L; Lou J; Jiang C J Control Release; 2010 Oct; 147(1):118-26. PubMed ID: 20609375 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen. Kang JY; Gao J; Shin DH; Alvarez C; Zhong W; Kwon GS Pharm Nanotechnol; 2016; 4(1):16-23. PubMed ID: 27774409 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles. Brajtburg J; Elberg S; Kobayashi GS; Medoff G Antimicrob Agents Chemother; 1990 Dec; 34(12):2415-6. PubMed ID: 2088196 [TBL] [Abstract][Full Text] [Related]
11. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B. Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042 [TBL] [Abstract][Full Text] [Related]
12. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593 [TBL] [Abstract][Full Text] [Related]
13. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl L aspartate) micelles. Yu BG; Okano T; Kataoka K; Sardari S; Kwon GS J Control Release; 1998 Dec; 56(1-3):285-91. PubMed ID: 9801451 [TBL] [Abstract][Full Text] [Related]
14. Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. Zia Q; Azhar A; Kamal MA; Aliev G; Owais M; Ashraf GM Curr Pharm Des; 2016; 22(7):792-803. PubMed ID: 26648472 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS). Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180 [TBL] [Abstract][Full Text] [Related]
16. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Legrand P; Romero EA; Cohen BE; Bolard J Antimicrob Agents Chemother; 1992 Nov; 36(11):2518-22. PubMed ID: 1489196 [TBL] [Abstract][Full Text] [Related]
17. Effect of aggregation state on the toxicity of different amphotericin B preparations. Espada R; Valdespina S; Alfonso C; Rivas G; Ballesteros MP; Torrado JJ Int J Pharm; 2008 Sep; 361(1-2):64-9. PubMed ID: 18599228 [TBL] [Abstract][Full Text] [Related]
18. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Frankenburg S; Glick D; Klaus S; Barenholz Y Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Gangadhar KN; Adhikari K; Srichana T Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597 [TBL] [Abstract][Full Text] [Related]
20. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]